Novack Jeffrey Adam sold $124K of CDNA

Novack Jeffrey Adam (Secretary and General Counsel) sold 2,688 shares of CareDx, Inc. (CDNA) at an average of $46.26 ($46.15–$46.75, $0.12M total) across 2 trades on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Novack Jeffrey Adam
Published Aug 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 7:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
high confidence
Mentioned
$CDNA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price range, and post-transaction holdings by the company’s Secretary and General Counsel under a 10b5-1 plan.

02

Market read

Traders may note insider selling, but 10b5-1 structure typically reduces signal strength versus discretionary sales.

03

What to watch

The filing does not indicate intent beyond the pre-arranged plan, and the article lacks any accompanying company-specific negative development.

Relevance 3/10Novelty 3/10Timing: filed Aug 6, transaction dated Aug 5

Background

The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).

Company-level read

Ticker impact

$CDNANeutralHigh confidence
Context

CareDx Form 4 shows insider (Secretary and General Counsel) sold 2,688 shares in open-market trades under a 10b5-1 plan on Aug 5.

Expected impact

Limited near-term impact; any reaction is likely muted unless paired with other negative company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the article provides no new fundamentals beyond the sale details.

Market effects

No clear sector read-through from a single routine 10b5-1 sale.

None.

None.

Counterpoint

10b5-1 sales can be misread as bearish; the plan timing may be unrelated to near-term performance expectations.

Key entities

  • CareDx, Inc.

    Subject of the Form 4 insider transaction disclosure (CDNA).

  • Novack Jeffrey Adam

    Secretary and General Counsel who sold 2,688 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.